tiprankstipranks
Trending News
More News >
Virpax Pharmaceuticals (VRPX)
OTHER OTC:VRPX
US Market

Virpax Pharmaceuticals (VRPX) Price & Analysis

Compare
221 Followers

VRPX Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Safety ProfileThe Molecular Envelope Technology (MET) study found no moderate-to-severe adverse events, indicating safety.
Study ResultsProbudur found to successfully reduce pain in rat model, with positive study results consistent with prior studies.
Bears Say
Financial ConstraintsInsufficient capital to materially advance into Phase 2 studies for both Probudur and Envelta.
Leadership InstabilityVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
Regulatory ComplianceVirpax received a deficiency letter from Nasdaq since the stock was trading below <$1 for 30 consecutive business days and has until a specific date to regain compliance.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.12%0.02%<0.01%99.98%
0.12%
Insiders
<0.01% Other Institutional Investors
99.98% Public Companies and Individual Investors

VRPX FAQ

What was Virpax Pharmaceuticals’s price range in the past 12 months?
Virpax Pharmaceuticals lowest stock price was $0.13 and its highest was $84.75 in the past 12 months.
    What is Virpax Pharmaceuticals’s market cap?
    Virpax Pharmaceuticals’s market cap is $433.38K.
      When is Virpax Pharmaceuticals’s upcoming earnings report date?
      Virpax Pharmaceuticals’s upcoming earnings report date is May 19, 2025 which is 45 days ago.
        How were Virpax Pharmaceuticals’s earnings last quarter?
        Virpax Pharmaceuticals released its earnings results on Mar 26, 2025. The company reported -$5.693 earnings per share for the quarter, beating the consensus estimate of -$9.25 by $3.557.
          Is Virpax Pharmaceuticals overvalued?
          According to Wall Street analysts Virpax Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Virpax Pharmaceuticals pay dividends?
            Virpax Pharmaceuticals does not currently pay dividends.
            What is Virpax Pharmaceuticals’s EPS estimate?
            Virpax Pharmaceuticals’s EPS estimate is -5.25.
              How many shares outstanding does Virpax Pharmaceuticals have?
              Virpax Pharmaceuticals has 1,242,504 shares outstanding.
                What happened to Virpax Pharmaceuticals’s price movement after its last earnings report?
                Virpax Pharmaceuticals reported an EPS of -$5.693 in its last earnings report, beating expectations of -$9.25. Following the earnings report the stock price went down -4.348%.
                  Which hedge fund is a major shareholder of Virpax Pharmaceuticals?
                  Currently, no hedge funds are holding shares in VRPX

                  Company Description

                  Virpax Pharmaceuticals

                  Virpax Pharmaceuticals (VRPX) is a clinical-stage pharmaceutical company focused on developing novel drug delivery systems to enhance the efficacy and safety of existing therapeutics. The company primarily operates in the pharmaceutical sector, specializing in pain management, neurological disorders, and anti-viral therapies. By leveraging proprietary delivery technologies, Virpax aims to optimize the delivery of active pharmaceutical ingredients, ultimately improving patient outcomes.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Scorpius Holdings
                  Salarius Pharmaceuticals
                  Processa Pharmaceuticals
                  GRI Bio
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis